# Ascentage Pharma Group International (AAPG)

Source: https://www.quantisnow.com/company/AAPG
Generated: 2026-11-14T22:36:31.846Z

- Ticker: AAPG
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0002023311

## Latest AAPG news and filings

- 2026-11-05 14:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6775211)
- 2026-11-04 23:30 UTC [Public Offering] [Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026](https://www.quantisnow.com/insight/ascentage-pharma-to-present-data-from-multiple-trials-including-an-6773759)
- 2026-11-03 12:30 UTC [Public Offering] [Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London](https://www.quantisnow.com/insight/ascentage-pharma-to-participate-in-two-upcoming-investor-conferences-in-6768427)
- 2026-10-28 13:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6760800)
- 2026-10-22 20:44 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6755428)
- 2026-10-21 20:55 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6753832)
- 2026-10-20 23:30 UTC [Public Offering] [Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL](https://www.quantisnow.com/insight/ascentage-pharmas-lisaftoclax-granted-breakthrough-therapy-designation-in-china-for-6752561)
- 2026-10-15 13:26 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6747625)
- 2026-10-14 12:43 UTC [Analyst Coverage Initiated] [Citigroup initiated coverage on Ascentage Pharma with a new price target](https://www.quantisnow.com/insight/citigroup-initiated-coverage-on-ascentage-pharma-with-a-new-price-6746078)
- 2026-10-13 12:44 UTC [Analyst Coverage Initiated] [Citizens initiated coverage on Ascentage Pharma with a new price target](https://www.quantisnow.com/insight/citizens-initiated-coverage-on-ascentage-pharma-with-a-new-price-6744416)
- 2026-09-28 22:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6728216)
- 2026-09-17 12:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6718564)
- 2026-09-02 12:00 UTC [Public Offering] [Ascentage Pharma to Participate in Four Upcoming Investor Conferences](https://www.quantisnow.com/insight/ascentage-pharma-to-participate-in-four-upcoming-investor-conferences-6702349)
- 2026-08-20 12:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6689486)
- 2026-08-19 23:00 UTC [Public Offering] [Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/ascentage-pharma-reports-2026-interim-unaudited-financial-results-and-provides-6689045)
- 2026-08-13 13:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6679691)
- 2026-08-13 12:00 UTC [Public Offering] [Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit](https://www.quantisnow.com/insight/ascentage-pharma-to-participate-in-the-evercore-2nd-annual-china-6679360)
- 2026-08-05 13:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6664358)
- 2026-08-05 12:00 UTC [Public Offering] [Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026](https://www.quantisnow.com/insight/ascentage-pharma-to-report-2026-six-month-interim-results-and-6664043)
- 2026-08-03 11:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6658696)
- 2026-08-02 23:30 UTC [Public Offering] [Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer](https://www.quantisnow.com/insight/ascentage-pharma-appoints-dr-faial-miyara-as-chief-business-officer-6658400)
- 2026-07-27 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6649731)
- 2026-07-26 23:30 UTC [Public Offering] [Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026](https://www.quantisnow.com/insight/ascentage-pharma-chairman-and-ceo-dr-dajun-yang-named-to-6648773)
- 2026-07-20 12:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6641987)
- 2026-07-18 01:51 UTC [SEC Form F-3ASR] [SEC Form F-3ASR filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-f-3asr-filed-by-ascentage-pharma-group-international-6641736)
- 2026-07-13 20:48 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6635614)
- 2026-06-30 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6620899)
- 2026-06-29 19:27 UTC [SEC Form 3] [SEC Form 3 filed by new insider Miyara Faical](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-miyara-faical-6618799)
- 2026-06-15 11:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6601776)
- 2026-06-14 23:30 UTC [Public Offering] [Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress](https://www.quantisnow.com/insight/ascentage-pharma-presents-multiple-clinical-updates-at-eha2026-congress-6601597)
- 2026-06-10 20:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6597180)
- 2026-06-10 12:30 UTC [Analyst Coverage Initiated] [B. Riley Securities initiated coverage on Ascentage Pharma with a new price target](https://www.quantisnow.com/insight/b-riley-securities-initiated-coverage-on-ascentage-pharma-with-a-6596527)
- 2026-06-01 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6580725)
- 2026-05-31 23:30 UTC [Public Offering] [Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026](https://www.quantisnow.com/insight/ascentage-pharma-presents-data-on-olverembatinib-in-cml-lbp-and-ph-6580250)
- 2026-05-31 23:30 UTC [Public Offering] [Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026](https://www.quantisnow.com/insight/ascentage-pharma-presents-its-first-dataset-on-mdm2-p53-inhibitor-alrizomadlin-6580248)
- 2026-05-31 23:30 UTC [Public Offering] [Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026](https://www.quantisnow.com/insight/ascentage-pharma-presents-updated-clinical-data-for-olverembatinib-as-second-line-6580247)
- 2026-05-28 21:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6577689)
- 2026-05-28 12:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by Ascentage Pharma Group International](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ascentage-pharma-group-international-6576319)
- 2026-05-22 20:44 UTC [SEC Form 4] [Chief Medical Officer Zhai Yifan converted options into 188,321 units of Ordinary Shares, increasing direct ownership by 30% to 405,280 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-zhai-yifan-converted-options-into-188321-units-6570278)
- 2026-05-22 20:18 UTC [SEC Form 4] [Chairman and CEO Yang Dajun converted options into 188,321 units of Ordinary Shares, increasing direct ownership by 9% to 1,193,569 units (SEC Form 4)](https://www.quantisnow.com/insight/chairman-and-ceo-yang-dajun-converted-options-into-188321-units-6569945)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AAPG
- Earnings history: https://www.quantisnow.com/earnings/AAPG
- Dividend history: https://www.quantisnow.com/dividends/AAPG
- Insider transactions: https://www.quantisnow.com/insiders/AAPG
- Options chain: https://www.quantisnow.com/options/AAPG
- SEC 8-K filings only: https://www.quantisnow.com/company/AAPG/8-k
- RSS and alerts for AAPG: https://www.quantisnow.com/docs/rss-feeds.md